drugset
drugset / Trial / NCT04660123

A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication

NCT04660123 ↗

Phase 4 Completed 959 enrolled Xijing Hospital of Digestive Diseases
NaSingle-groupOpen-labelTreatment

Summary

To observe the eradication rate of H. pylori infection, symptom improvement and the incidence of adverse effects in patients using a bismuth colloidal pectin granules quadruple therapy.

Timeline

Start
2020-12-20
Primary completion
2021-12-30
Completion
2021-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bismuth Colloidal Pectin Granules Unknown 150 mg Oral
Background Amoxicillin Other / unclassified 1000 mg Oral
Background Clarithromycin Small molecule 500 mg Oral
Background Esomeprazole Small molecule 20 mg Oral
Background Furazolidone Small molecule 100 mg Oral
Background Lansoprazole Other / unclassified 30 mg Oral
Background Levofloxacin Small molecule 500 unknown Oral
Background Metronidazole Small molecule 400 mg Oral
Background Omeprazole Other / unclassified 20 mg Oral
Background Pantoprazole Other / unclassified 40 mg Oral
Background Rabeprazole Small molecule 10 mg Oral
Background Rabeprazole Small molecule 20 mg Oral
Background Tetracycline Unknown 500 mg Oral
Background alprazole Unknown 5 mg Oral

Indications

Helicobacter pylori infectious disease gastric cancer